QbD In Solid Lipid Nanoparticles To Enhance Blood-Brain Barrier Permeation For Alzheimer’s Therapy
Suman Bala, Panner Selvam · European journal of parenteral & pharmaceutical sciences · 2025
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
European journal of parenteral & pharmaceutical sciences · OpenAlex · article · 2025
Abstract
Alzheimer’s disease (AD) continues to pose a major therapeutic challenge, primarily due to the restricted ability of drugs to traverse the blood-brain barrier (BBB). Solid lipid nanoparticles have gained attention as effective nanocarriers capable of addressing this limitation, thanks to their favourable biocompatibility, capacity to improve drug stability, and potential for sustained drug release. This research investigates the application of the QbD framework in formulating SLNs aimed at enhancing BBB penetration and achieving targeted drug delivery for AD management.
The finalized SLN formulation exhibited significantly improved permeability across the BBB, as evidenced by both in-vitro and in-vivo assessments. These findings suggest a promising advancement in AD therapeutics. Moreover, the use of QbD principles in the development process contributes to the creation of consistent, high-quality nanoparticle systems that meet current regulatory standards for nanomedicine. Keywords: Alzheimer’s disease, Rivastigmine, Central nervous system, Dementia, Solid lipid nanoparticle, Nanotechnology.
Open the resolved locator · 10.37521/ejpps30210
Metadata licence: OpenAlex metadata (CC0)